TABLE OF CONTENT 1 EXECUTIVE SUMMARY 1.1 OVERVIEW 14 1.1.1 MARKET SYPNOSIS 14 2 MARKET INTRODUCTION 2.1 DEFINITION 15 2.2 SCOPE OF THE STUDY 15 2.3 RESEARCH OBJECTIVE 15 2.4 MARKET STRUCTURE 15 2.5 ASSUMPTIONS & LIMITATIONS 16 3 RESEARCH METHODOLOGY 3.1 DATA MINING 17 3.2 SECONDARY RESEARCH 18 3.3 PRIMARY RESEARCH 18 3.4 BREAKDOWN OF PRIMARY RESPONDENTS 19 3.5 FORECASTING TECHNIQUES 20 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 21 3.6.1 BOTTOM-UP APPROACH 22 3.6.2 TOP-DOWN APPROACH 22 3.7 DATA TRIANGULATION 23 3.8 VALIDATION 23 4 MARKET DYNAMICS 4.1 OVERVIEW 24 4.2 DRIVERS 25 4.2.1 GROWING CASES OF CANCER 25 4.2.2 RISE IN GASTROINTESTINAL DISEASES 25 4.2.3 INCREASING GERIATRIC POPULATION, SEDENTARY LIFESTYLE, AND UNHEALTHY DIET 25 4.3 RESTRAINTS 26 4.3.1 HIGH PREFERENCE FOR HOME REMEDIES 26 4.4 OPPORTUNITIES 27 4.4.1 COLLABORATIONS BETWEEN LARGE DRUG MANUFACTURING COMPANY AND SMALL COMPANIES 27 5 MARKET FACTOR ANALYSIS 5.1 VALUE CHAIN ANALYSIS 28 5.1.1 R&D AND DESIGNING 29 5.1.2 MANUFACTURING 29 5.1.3 DISTRIBUTION & SALES 29 5.1.4 POST-SALES SERVICES 29 5.2 PORTER’S FIVE FORCES MODEL 30 5.2.1 BARGAINING POWER OF SUPPLIERS 31 5.2.2 BARGAINING POWER OF BUYERS 31 5.2.3 THREAT OF NEW ENTRANTS 31 5.2.4 THREAT OF SUBSTITUTES 31 5.2.5 INTENSITY OF RIVALRY 31 6 GLOBAL NAUSEA MEDICINE MARKET, BY TYPE 6.1 OVERVIEW 32 6.2 ANTAGONISTS 33 6.3 ANTIHISTAMINES 33 6.4 CANNABINOIDS 34 6.5 OTHERS 34 7 GLOBAL NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION 7.1 OVERVIEW 35 7.2 INTRAVENOUS 36 7.3 ORAL 36 7.4 TRANSDERMAL 37 8 GLOBAL NAUSEA MEDICINE MARKET, BY INDICATION 8.1 OVERVIEW 38 8.2 ONCOLOGY 39 8.3 GASTROESOPHAGEAL REFLUX DISEASE (GERD) 39 8.4 MOTION SICKNESS AND SEASICKNESS 40 8.5 OTHERS 40 9 GLOBAL NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL 9.1 OVERVIEW 41 9.2 HOSPITALS PHARMACY/ RETAIL PHARMACY 42 9.3 ONLINE 42 10 GLOBAL NAUSEA MEDICINE MARKET, BY REGION 10.1 OVERVIEW 43 10.2 AMERICAS 44 10.2.1 NORTH AMERICA 46 10.2.1.1 US 48 10.2.1.2 CANADA 49 10.2.2 SOUTH AMERICA 51 10.3 EUROPE 53 10.3.1 WESTERN EUROPE 55 10.3.1.1 GERMANY 57 10.3.1.2 FRANCE 58 10.3.1.3 UK 60 10.3.1.4 ITALY 61 10.3.1.5 SPAIN 62 10.3.1.6 REST OF WESTERN EUROPE 64 10.3.2 EASTERN EUROPE 65 10.4 ASIA-PACIFIC 67 10.4.1 CHINA 69 10.4.2 JAPAN 70 10.4.3 INDIA 72 10.4.4 AUSTRALIA 73 10.4.5 SOUTH KOREA 74 10.4.6 REST OF ASIA-PACIFIC 76 10.5 MIDDLE EAST & AFRICA 78 10.5.1 MIDDLE EAST 80 10.5.2 AFRICA 81 11 COMPETITIVE LANDSCAPE 11.1 OVERVIEW 83 11.2 MAJOR PLAYERS IN THE GLOBAL NAUSEA MEDICINE MARKET 83 11.3 COMPETITIVE BENCHMARKING 84 11.4 COMPETITOR DASHBOARD 85 11.5 KEY DEVELOPMENTS & GROWTH STRATEGIES 85 11.5.1 ACQUISITIONS 85 12 COMPANY PROFILES 12.1 SANOFI S.A. 86 12.1.1 COMPANY OVERVIEW 86 12.1.2 FINANCIAL OVERVIEW 86 12.1.3 PRODUCTS/SERVICES OFFERED 87 12.1.4 KEY DEVELOPMENTS 87 12.1.5 SWOT ANALYSIS 87 12.1.6 KEY STRATEGIES 87 12.2 NOVARTIS AG 88 12.2.1 COMPANY OVERVIEW 88 12.2.2 FINANCIAL OVERVIEW 88 12.2.3 PRODUCTS/SERVICES OFFERED 89 12.2.4 KEY DEVELOPMENTS 89 12.2.5 SWOT ANALYSIS 89 12.2.6 KEY STRATEGIES 89 12.3 MERCK & CO., INC. 90 12.3.1 COMPANY OVERVIEW 90 12.3.2 FINANCIAL OVERVIEW 90 12.3.3 PRODUCTS/SERVICES OFFERED 91 12.3.4 KEY DEVELOPMENTS 91 12.3.5 SWOT ANALYSIS 91 12.3.6 KEY STRATEGIES 91 12.4 GLAXOSMITHKLINE PLC 92 12.4.1 COMPANY OVERVIEW 92 12.4.2 FINANCIAL OVERVIEW 92 12.4.3 PRODUCTS/SERVICES OFFERED 93 12.4.4 KEY DEVELOPMENTS 93 12.4.5 SWOT ANALYSIS 93 12.4.6 KEY STRATEGIES 94 12.5 MYLAN NV 95 12.5.1 COMPANY OVERVIEW 95 12.5.2 FINANCIAL OVERVIEW 95 12.5.3 PRODUCTS/SERVICES OFFERED 96 12.5.4 KEY DEVELOPMENTS 96 12.5.5 SWOT ANALYSIS 96 12.5.6 KEY STRATEGIES 96 12.6 PFIZER INC. 97 12.6.1 COMPANY OVERVIEW 97 12.6.2 FINANCIAL OVERVIEW 97 12.6.3 PRODUCTS/SERVICES OFFERED 98 12.6.4 KEY DEVELOPMENTS 98 12.6.5 SWOT ANALYSIS 98 12.6.6 KEY STRATEGIES 98 12.7 F. HOFFMANN-LA ROCHE LTD 99 12.7.1 COMPANY OVERVIEW 99 12.7.2 FINANCIAL OVERVIEW 99 12.7.3 PRODUCTS/SERVICES OFFERED 100 12.7.4 KEY DEVELOPMENTS 100 12.7.5 SWOT ANALYSIS 100 12.7.6 KEY STRATEGIES 100 12.8 ASTRAZENECA 101 12.8.1 COMPANY OVERVIEW 101 12.8.2 FINANCIAL OVERVIEW 101 12.8.3 PRODUCTS/SERVICES OFFERED 102 12.8.4 KEY DEVELOPMENTS 102 12.8.5 SWOT ANALYSIS 102 12.8.6 KEY STRATEGIES 102 12.9 CIPLA INC. 103 12.9.1 COMPANY OVERVIEW 103 12.9.2 FINANCIAL OVERVIEW 103 12.9.3 PRODUCTS/SERVICES OFFERED 104 12.9.4 KEY DEVELOPMENTS 104 12.9.5 SWOT ANALYSIS 104 12.9.6 KEY STRATEGIES 104 13 APPENDIX 13.1 REFERENCES 105 13.2 RELATED REPORTS 105

LIST OF TABLES TABLE 1 LIST OF ASSUMPTIONS 16 TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 19 TABLE 3 GLOBAL NAUSEA MEDICINE MARKET, BY TYPE, 2016–2027 (USD MILLION) 32 TABLE 4 GLOBAL NAUSEA MEDICINE MARKET, FOR ANTAGONISTS, BY REGION, 2016–2027 (USD MILLION) 33 TABLE 5 GLOBAL NAUSEA MEDICINE MARKET, FOR ANTIHISTAMINES, BY REGION, 2016–2027 (USD MILLION) 33 TABLE 6 GLOBAL NAUSEA MEDICINE MARKET, FOR CANNABINOIDS, BY REGION, 2016–2027 (USD MILLION) 34 TABLE 7 GLOBAL NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2016–2027 (USD MILLION) 35 TABLE 8 GLOBAL NAUSEA MEDICINE MARKET, FOR INTRAVENOUS, BY REGION 2016–2027 (USD MILLION) 36 TABLE 9 GLOBAL NAUSEA MEDICINE MARKET, FOR ORAL, BY REGION 2016–2027 (USD MILLION) 36 TABLE 10 GLOBAL NAUSEA MEDICINE MARKET, FOR TRANSDERMAL, BY REGION 2016–2027 (USD MILLION) 37 TABLE 11 GLOBAL NAUSEA MEDICINE MARKET, BY INDICATION, 2016–2027 (USD MILLION) 38 TABLE 12 GLOBAL NAUSEA MEDICINE MARKET, FOR ONCOLOGY, BY REGION, 2016–2027 (USD MILLION) 39 TABLE 13 GLOBAL NAUSEA MEDICINE MARKET, FOR GASTROESOPHAGEAL REFLUX DISEASE (GERD), BY REGION, 2016–2027 (USD MILLION) 39 TABLE 14 GLOBAL NAUSEA MEDICINE MARKET, FOR MOTION SICKNESS AND SEASICKNESS, BY REGION, 2016–2027 (USD MILLION) 40 TABLE 15 GLOBAL NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2016–2027 (USD MILLION) 41 TABLE 16 GLOBAL NAUSEA MEDICINE MARKET, FOR HOSPITALS PHARMACY/ RETAIL PHARMACY, BY REGION, 2016–2027 (USD MILLION) 42 TABLE 17 GLOBAL NAUSEA MEDICINE MARKET, FOR ONLINE, BY REGION,2016–2027 (USD MILLION) 42 TABLE 18 GLOBAL NAUSEA MEDICINE MARKET, BY REGION 2016–2027 (USD MILLION) 43 TABLE 19 AMERICAS NAUSEA MEDICINE MARKET, BY REGION, 2016–2027 (USD MILLION) 44 TABLE 20 AMERICAS NAUSEA MEDICINE MARKET, BY TYPE, 2016–2027 (USD MILLION) 45 TABLE 21 AMERICAS NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2016–2027 (USD MILLION) 45 TABLE 22 AMERICAS NAUSEA MEDICINE MARKET, BY INDICATION, 2016–2027 (USD MILLION) 45 TABLE 23 AMERICAS NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2016–2027 (USD MILLION) 46 TABLE 24 NORTH AMERICA NAUSEA MEDICINE MARKET, BY REGION, 2016–2027 (USD MILLION) 46 TABLE 25 NORTH AMERICA NAUSEA MEDICINE MARKET, BY TYPE, 2016–2027 (USD MILLION) 47 TABLE 26 NORTH AMERICA NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2016–2027 (USD MILLION) 47 TABLE 27 NORTH AMERICA NAUSEA MEDICINE MARKET, BY INDICATION, 2016–2027 (USD MILLION) 47 TABLE 28 NORTH AMERICA NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2016–2027 (USD MILLION) 48 TABLE 29 US NAUSEA MEDICINE MARKET, BY TYPE, 2016–2027 (USD MILLION) 48 TABLE 30 US NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2016–2027 (USD MILLION) 48 TABLE 31 US NAUSEA MEDICINE MARKET, BY INDICATION, 2016–2027 (USD MILLION) 49 TABLE 32 US NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2016–2027 (USD MILLION) 49 TABLE 33 CANADA NAUSEA MEDICINE MARKET, BY TYPE, 2016–2027 (USD MILLION) 49 TABLE 34 CANADA NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2016–2027 (USD MILLION) 50 TABLE 35 CANADA NAUSEA MEDICINE MARKET, BY INDICATION, 2016–2027 (USD MILLION) 50 TABLE 36 CANADA NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2016–2027 (USD MILLION) 50 TABLE 37 SOUTH AMERICA NAUSEA MEDICINE MARKET, BY TYPE, 2016–2027 (USD MILLION) 51 TABLE 38 SOUTH AMERICA NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2016–2027 (USD MILLION) 51 TABLE 39 SOUTH AMERICA NAUSEA MEDICINE MARKET, BY INDICATION, 2016–2027 (USD MILLION) 51 TABLE 40 SOUTH AMERICA NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2016–2027 (USD MILLION) 52 TABLE 41 EUROPE NAUSEA MEDICINE MARKET, BY REGION, 2016–2027 (USD MILLION) 53 TABLE 42 EUROPE NAUSEA MEDICINE MARKET, BY TYPE, 2016–2027 (USD MILLION) 54 TABLE 43 EUROPE NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2016–2027 (USD MILLION) 54 TABLE 44 EUROPE NAUSEA MEDICINE MARKET, BY INDICATION, 2016–2027 (USD MILLION) 54 TABLE 45 EUROPE NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2016–2027 (USD MILLION) 55 TABLE 46 WESTERN EUROPE NAUSEA MEDICINE MARKET, BY REGION, 2016–2027 (USD MILLION) 55 TABLE 47 WESTERN EUROPE NAUSEA MEDICINE MARKET, BY TYPE, 2016–2027 (USD MILLION) 56 TABLE 48 WESTERN EUROPE NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2016–2027 (USD MILLION) 56 TABLE 49 WESTERN EUROPE NAUSEA MEDICINE MARKET, BY INDICATION, 2016–2027 (USD MILLION) 56 TABLE 50 WESTERN EUROPE NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2016–2027 (USD MILLION) 57 TABLE 51 GERMANY NAUSEA MEDICINE MARKET, BY TYPE, 2016–2027 (USD MILLION) 57 TABLE 52 GERMANY NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2016–2027 (USD MILLION) 57 TABLE 53 GERMANY NAUSEA MEDICINE MARKET, BY INDICATION, 2016–2027 (USD MILLION) 58 TABLE 54 GERMANY NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2016–2027 (USD MILLION) 58 TABLE 55 FRANCE NAUSEA MEDICINE MARKET, BY TYPE, 2016–2027 (USD MILLION) 58 TABLE 56 FRANCE NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2016–2027 (USD MILLION) 59 TABLE 57 FRANCE NAUSEA MEDICINE MARKET, BY INDICATION, 2016–2027 (USD MILLION) 59 TABLE 58 FRANCE NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2016–2027 (USD MILLION) 59 TABLE 59 UK NAUSEA MEDICINE MARKET, BY TYPE, 2016–2027 (USD MILLION) 60 TABLE 60 UK NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2016–2027 (USD MILLION) 60 TABLE 61 UK NAUSEA MEDICINE MARKET, BY INDICATION, 2016–2027 (USD MILLION) 60 TABLE 62 UK NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2016–2027 (USD MILLION) 61 TABLE 63 ITALY NAUSEA MEDICINE MARKET, BY TYPE, 2016–2027 (USD MILLION) 61 TABLE 64 ITALY NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2016–2027 (USD MILLION) 61 TABLE 65 ITALY NAUSEA MEDICINE MARKET, BY INDICATION, 2016–2027 (USD MILLION) 62 TABLE 66 ITALY NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2016–2027 (USD MILLION) 62 TABLE 67 SPAIN NAUSEA MEDICINE MARKET, BY TYPE, 2016–2027 (USD MILLION) 62 TABLE 68 SPAIN NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2016–2027 (USD MILLION) 63 TABLE 69 SPAIN NAUSEA MEDICINE MARKET, BY INDICATION, 2016–2027 (USD MILLION) 63 TABLE 70 SPAIN NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2016–2027 (USD MILLION) 63 TABLE 71 REST OF WESTERN EUROPE NAUSEA MEDICINE MARKET, BY TYPE, 2016–2027 (USD MILLION) 64 TABLE 72 REST OF WESTERN EUROPE NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2016–2027 (USD MILLION) 64 TABLE 73 REST OF WESTERN EUROPE NAUSEA MEDICINE MARKET, BY INDICATION, 2016–2027 (USD MILLION) 64 TABLE 74 REST OF WESTERN EUROPE NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2016–2027 (USD MILLION) 65 TABLE 75 EASTERN EUROPE NAUSEA MEDICINE MARKET, BY TYPE, 2016–2027 (USD MILLION) 65 TABLE 76 EASTERN EUROPE NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2016–2027 (USD MILLION) 65 TABLE 77 EASTERN EUROPE NAUSEA MEDICINE MARKET, BY INDICATION, 2016–2027 (USD MILLION) 66 TABLE 78 EASTERN EUROPE NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2016–2027 (USD MILLION) 66 TABLE 79 ASIA-PACIFIC NAUSEA MEDICINE MARKET, BY COUNTRY, 2016–2027 (USD MILLION) 67 TABLE 80 ASIA-PACIFIC NAUSEA MEDICINE MARKET, BY TYPE, 2016–2027 (USD MILLION) 68 TABLE 81 ASIA-PACIFIC NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2016–2027 (USD MILLION) 68 TABLE 82 ASIA-PACIFIC NAUSEA MEDICINE MARKET, BY INDICATION, 2016–2027 (USD MILLION) 68 TABLE 83 ASIA-PACIFIC NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2016–2027 (USD MILLION) 69 TABLE 84 CHINA NAUSEA MEDICINE MARKET, BY TYPE, 2016–2027 (USD MILLION) 69 TABLE 85 CHINA NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2016–2027 (USD MILLION) 69 TABLE 86 CHINA NAUSEA MEDICINE MARKET, BY INDICATION, 2016–2027 (USD MILLION) 70 TABLE 87 CHINA NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2016–2027 (USD MILLION) 70 TABLE 88 JAPAN NAUSEA MEDICINE MARKET, BY TYPE, 2016–2027 (USD MILLION) 70 TABLE 89 JAPAN NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2016–2027 (USD MILLION) 71 TABLE 90 JAPAN NAUSEA MEDICINE MARKET, BY INDICATION, 2016–2027 (USD MILLION) 71 TABLE 91 JAPAN NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2016–2027 (USD MILLION) 71 TABLE 92 INDIA NAUSEA MEDICINE MARKET, BY TYPE, 2016–2027 (USD MILLION) 72 TABLE 93 INDIA NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2016–2027 (USD MILLION) 72 TABLE 94 INDIA NAUSEA MEDICINE MARKET, BY INDICATION, 2016–2027 (USD MILLION) 72 TABLE 95 INDIA NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2016–2027 (USD MILLION) 73 TABLE 96 AUSTRALIA NAUSEA MEDICINE MARKET, BY TYPE, 2016–2027 (USD MILLION) 73 TABLE 97 AUSTRALIA NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2016–2027 (USD MILLION) 73 TABLE 98 AUSTRALIA NAUSEA MEDICINE MARKET, BY INDICATION, 2016–2027 (USD MILLION) 74 TABLE 99 AUSTRALIA NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2016–2027 (USD MILLION) 74 TABLE 100 SOUTH KOREA NAUSEA MEDICINE MARKET, BY TYPE, 2016–2027 (USD MILLION) 74 TABLE 101 SOUTH KOREA NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2016–2027 (USD MILLION) 75 TABLE 102 SOUTH KOREA NAUSEA MEDICINE MARKET, BY INDICATION, 2016–2027 (USD MILLION) 75 TABLE 103 SOUTH KOREA NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2016–2027 (USD MILLION) 75 TABLE 104 REST OF ASIA-PACIFIC NAUSEA MEDICINE MARKET, BY TYPE, 2016–2027 (USD MILLION) 76 TABLE 105 REST OF ASIA-PACIFIC NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2016–2027 (USD MILLION) 76 TABLE 106 REST OF ASIA-PACIFIC NAUSEA MEDICINE MARKET, BY INDICATION, 2016–2027 (USD MILLION) 76 TABLE 107 REST OF ASIA-PACIFIC NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2016–2027 (USD MILLION) 77 TABLE 108 MIDDLE EAST & AFRICA NAUSEA MEDICINE MARKET, BY REGION 2016–2027 (USD MILLION) 78 TABLE 109 MIDDLE EAST & AFRICA NAUSEA MEDICINE MARKET, BY TYPE, 2016–2027 (USD MILLION) 79 TABLE 110 MIDDLE EAST & AFRICA NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2016–2027 (USD MILLION) 79 TABLE 111 MIDDLE EAST & AFRICA NAUSEA MEDICINE MARKET, BY INDICATION, 2016–2027 (USD MILLION) 79 TABLE 112 MIDDLE EAST & AFRICA NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2016–2027 (USD MILLION) 80 TABLE 113 MIDDLE EAST NAUSEA MEDICINE MARKET, BY TYPE, 2016–2027 (USD MILLION) 80 TABLE 114 MIDDLE EAST NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2016–2027 (USD MILLION) 80 TABLE 115 MIDDLE EAST NAUSEA MEDICINE MARKET, BY INDICATION, 2016–2027 (USD MILLION) 81 TABLE 116 MIDDLE EAST NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2016–2027 (USD MILLION) 81 TABLE 117 AFRICA NAUSEA MEDICINE MARKET, BY TYPE, 2016–2027 (USD MILLION) 81 TABLE 118 AFRICA NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2016–2027 (USD MILLION) 82 TABLE 119 AFRICA NAUSEA MEDICINE MARKET, BY INDICATION, 2016–2027 (USD MILLION) 82 TABLE 120 AFRICA NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2016–2027 (USD MILLION) 82 TABLE 121 MAJOR PLAYERS IN THE GLOBAL NAUSEA MEDICINE MARKET 83 TABLE 122 ACQUISITIONS 85 TABLE 123 SANOFI S.A.: PRODUCTS/SERVICES OFFERED 87 TABLE 124 NOVARTIS AG: PRODUCTS/SERVICES OFFERED 89 TABLE 125 MERCK & CO., INC.: PRODUCTS/SERVICES OFFERED 91 TABLE 126 GLAXOSMITHKLINE PLC: PRODUCTS/SERVICES OFFERED 93 TABLE 127 GLAXOSMITHKLINE PLC: KEY DEVELOPMENTS 93 TABLE 128 MYLAN NV: PRODUCTS/SERVICES OFFERED 96 TABLE 129 PFIZER INC.: PRODUCTS/SERVICES OFFERED 98 TABLE 130 F. HOFFMANN-LA ROCHE LTD: PRODUCTS/SERVICES OFFERED 100 TABLE 131 ASTRAZENECA: PRODUCTS/SERVICES OFFERED 102 TABLE 132 CIPLA INC.: PRODUCTS/SERVICES OFFERED 104

Novartis AG (Switzerland), Merck & Co., Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), GlaxoSmithKline PLC (UK), Pfizer Inc. (US), Sanofi S.A. (France), Mylan NV (US), AstraZeneca (UK), Cipla Inc. (India), and others